GENEVA, Switzerland, May 3, 2010 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced it has been named as one of the best places to work in the industry by The Scientist magazine. Merck Serono ranked number 24 among the top institutions. More than 240 companies participated in the survey overall.

It's an honor to earn recognition from The Scientist as one of the top companies to work for in the industry, said Bernhard Kirschbaum, Head of Global Research and Development, Merck Serono. It is the commitment, focus and world-class expertise of our employees that truly makes a difference to not only our organization, but to patients living with unmet medical needs. Our employees play a critical role in ensuring that we strengthen our reputation as a leader in the industry, and continue our mission of advancing science and medicine.

Merck Serono's scores reflected the company's commitment to its employees, with high marks in the areas of remuneration and benefits, and training and development.

The Scientist's May issue is available now in print and online.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.

Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alpha), endocrine and metabolic disorders (Saizen(R) and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage(R), metformin), (Concor(R), bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available in all markets.

With an annual RD expenditure of more than EUR 1 billion, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 33,600 employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck Co. was expropriated and has been an independent company ever since.

For more information, please visit or

SOURCE: Merck Serono S A

CONTACT: Merck Serono, 9 Chemin des Mines, Media Relations, 1202 Geneva,Tel.: +41-22-414-36 00, Switzerland